Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2019

Open Access 01-12-2019 | Isoniazid | Research

Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB

Authors: Noura M. Al-Mutairi, Suhail Ahmad, Eiman M. Mokaddas

Published in: European Journal of Medical Research | Issue 1/2019

Login to get access

Abstract

Background

Increasing incidence of multidrug-resistant Mycobacterium tuberculosis infections is hampering global tuberculosis control efforts. Kuwait is a low-tuberculosis-incidence country, and ~ 1% of M. tuberculosis strains are resistant to rifampicin and isoniazid (MDR-TB). This study detected mutations in seven genes predicting resistance to rifampicin, isoniazid, pyrazinamide, ethambutol and streptomycin in MDR-TB strains. Sequence data were combined with spoligotypes for detecting local transmission of MDR-TB in Kuwait.

Methods

Ninety-three MDR-TB strains isolated from 12 Kuwaiti and 81 expatriate patients and 50 pansusceptible strains were used. Phenotypic drug susceptibility was determined by MGIT 460 TB/960 system. Mutations conferring resistance to rifampicin, isoniazid, pyrazinamide, ethambutol and streptomycin were detected by genotype MTBDRplus assay and/or PCR sequencing of three rpoB regions, katG codon 315 (katG315) + inhA regulatory region, pncA, three embB regions and rpsL + rrs-500–900 regions. Spoligotyping kit was used, spoligotypes were identified by SITVIT2, and phylogenetic tree was constructed by using MIRU-VNTRplus software. Phylogenetic tree was also constructed from concatenated sequences by MEGA7 software. Additional PCR sequencing of gidB and rpsA was performed for cluster isolates.

Results

Pansusceptible isolates contained wild-type sequences. Mutations in rpoB and katG and/or inhA were detected in 93/93 and 92/93 MDR-TB strains, respectively. Mutations were also detected for pyrazinamide resistance, ethambutol resistance and streptomycin resistance in MDR-TB isolates in pncA, embB and rpsL + rrs, respectively. Spoligotyping identified 35 patterns with 18 isolates exhibiting unique patterns while 75 isolates grouped in 17 patterns. Beijing genotype was most common (32/93), and 11 isolates showed nine orphan patterns. Phylogenetic analysis of concatenated sequences showed unique patterns for 51 isolates while 42 isolates grouped in 16 clusters. Interestingly, 22 isolates in eight clusters by both methods were isolated from TB patients typically within a span of 2 years. Five of eight clusters were confirmed by additional gidB and rpsA sequence data.

Conclusions

Our study provides the first insight into molecular epidemiology of MDR-TB in Kuwait and identified several potential clusters of local transmission of MDR-TB involving 2–6 subjects which had escaped detection by routine surveillance studies. Prospective detection of resistance-conferring mutations can identify possible cases of local transmission of MDR-TB in low MDR-TB settings.
Appendix
Available only for authorised users
Literature
1.
World Health Organization. Global tuberculosis report 2018. WHO/CDS/TB/2018.20. Geneva: WHO; 2018.
2.
3.
Pareek M, Greenaway C, Noori T, Munoz J, Zenner D. The impact of migration on tuberculosis epidemiology and control in high-income countries: a review. BMC Med. 2016;14:48.PubMedPubMedCentralCrossRef
4.
Yates TA, Khan PY, Knight GM, Taylor JG, McHugh TD, Lipman M, et al. The transmission of Mycobacterium tuberculosis in high burden settings. Lancet Infect Dis. 2016;16:227–38.PubMedCrossRef
5.
Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. J Infect Pub Health. 2014;2014(7):75–91.CrossRef
6.
Dheda K, Chang KC, Guglielmetti L, Furin J, Schaaf HS, Chesov D, et al. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Microbiol Infect. 2017;23:131–40.PubMedCrossRef
7.
Miotto P, Zhang Y, Cirillo DM, Yam WC. Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology. 2018;23:1098–113.PubMedCrossRef
8.
Schön T, Miotto P, Köser CU, Viveiros M, Böttger E, Cambau E. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clin Microbiol Infect. 2017;23:154–60.PubMedCrossRef
9.
CRyPTIC Consortium and the 100,000 Genomes Project, Allix-Béguec C, Arandjelovic I, Bi L, Beckert P, Bonnet M, et al. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N Engl J Med. 2018;379:1403–15.CrossRef
10.
Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, et al. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infect Dis. 2018;18:675–83.PubMedPubMedCentralCrossRef
11.
Miotto P, Cabibbe AM, Borroni E, Degano M, Cirillo DM. Role of disputed mutations in the rpoB gene in interpretation of automated liquid MGIT culture results for rifampin susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2018;56:e01599.PubMedPubMedCentralCrossRef
12.
Al-Mutairi NM, Ahmad S, Mokaddas E, Eldeen HS, Joseph S. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis. BMC Infect Dis. 2019;19:3.PubMedPubMedCentralCrossRef
13.
Jajou R, van der Laan T, de Zwaan R, Kamst M, Mulder A, de Neeling A, et al. WGS more accurately predicts susceptibility of Mycobacterium tuberculosis to first-line drugs than phenotypic testing. J Antimicrob Chemother. 2019;74:2605–16.PubMedCrossRef
14.
Mokaddas E, Ahmad S, Samir I. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996–2005. Int J Tuberc Lung Dis. 2008;12:319–25.PubMed
15.
Ahmad S, Mokaddas E, Al-Mutairi NM. Epidemiology of tuberculosis and multidrug-resistant tuberculosis in the Middle East Region. Expert Rev Anti Infective Ther. 2018;16:709–21.CrossRef
16.
Abal AT, Ahmad S, Mokaddas E. Variations in the occurrence of the S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. Microb Drug Resist. 2002;8:99–105.PubMedCrossRef
17.
Ahmad S, Mokaddas E, Fares E. Characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from Kuwait and Dubai. Diagn Microbiol Infect Dis. 2002;44:245–52.PubMedCrossRef
18.
Ahmad S, Mokaddas E. The occurrence of rare rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from Kuwait. Int J Antimicrob Agents. 2005;26:205–12.PubMedCrossRef
19.
Ahmad S, Al-Mutairi NM, Mokaddas E. Variations in the occurrence of specific rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis strains isolated from patients of different ethnic groups in Kuwait. Indian J Med Res. 2012;135:756–62.PubMedPubMedCentral
20.
Mokaddas E, Ahmad S, Abal AT, Al-Shami AS. Molecular fingerprinting reveals familial transmission of rifampin-resistant tuberculosis in Kuwait. Ann Saudi Med. 2005;25:150–3.PubMedPubMedCentralCrossRef
21.
Spies FS, Ribeiro AW, Ramos DF, Ribeiro MO, Martin A, Palomino JC, et al. Streptomycin resistance and lineage-specific polymorphisms in Mycobacterium tuberculosis gidB gene. J Clin Microbiol. 2011;49:2625–30.PubMedPubMedCentralCrossRef
22.
Ramirez-Busby SM, Rodwell TC, Fink L, Catanzaro D, Jackson RL, Pettigrove M, et al. Multinational analysis of mutations and heterogeneity in PZase, RpsA, and PanD associated with pyrazinamide resistance in M/XDR Mycobacterium tuberculosis. Sci Rep. 2017;7:3790.PubMedPubMedCentralCrossRef
23.
Ahmad S, Mokaddas E, Al-Mutairi N, Eldeen HS, Mohammadi S. Discordance across phenotypic and molecular methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a low TB incidence country. PLoS ONE. 2016;11:e0153563.PubMedPubMedCentralCrossRef
24.
Mokaddas E, Ahmad S. Development and evaluation of a multiplex PCR for rapid detection and differentiation of Mycobacterium tuberculosis complex members from non-tuberculous mycobacteria. Jap J Infect Dis. 2007;60:140–4.
25.
Ahmad S, Fares E, Araj GF, Chugh TD, Mustafa AS. Prevalence of S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Dubai and Beirut. Int J Tuberc Lung Dis. 2002;6:920–6.PubMed
26.
Al-Mutairi N, Ahmad S, Mokaddas E. Performance comparison of four methods for rapid detection of multidrug-resistant Mycobacterium tuberculosis strains. Int J Tuberc Lung Dis. 2011;15:110–5.PubMed
27.
Ahmad S, Jaber AA, Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis (Edinburgh). 2007;87:123–9.CrossRef
28.
Al-Mutairi N, Ahmad S, Mokaddas E. Molecular screening versus phenotypic susceptibility testing of multidrug-resistant Mycobacterium tuberculosis isolates for streptomycin and ethambutol. Microb Drug Resist. 2018;24:923–31.PubMedCrossRef
29.
Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. MBio. 2014;5:e01819.PubMedPubMedCentralCrossRef
30.
Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35:907–14.PubMedPubMedCentral
31.
32.
Feuerriegel S, Köser CU, Niemann S. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother. 2014;69:1205–10.PubMedCrossRef
33.
World Health Organization. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva: World Health Organization; 2012.
34.
Van Soolingen D. Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements. J Int Med. 2001;249:1–26.CrossRef
35.
Gauthier M, Bidault F, Mosnier A, Bablishvili N, Tukvadze N, Somphavong S, et al. High-throughput mycobacterial interspersed repetitive-unit-variable-number tandem-repeat genotyping for Mycobacterium tuberculosis epidemiological studies. J Clin Microbiol. 2015;53:498.PubMedPubMedCentralCrossRef
36.
Merker M, Kohl TA, Niemann S, Supply P. The evolution of strain typing in the Mycobacterium tuberculosis complex. Adv Exp Med Biol. 2017;1019:43–78.PubMedCrossRef
37.
38.
Meehan CJ, Moris P, Kohl TA, Pečerska J, Akter S, Merker M, et al. The relationship between transmission time and clustering methods in Mycobacterium tuberculosis epidemiology. EBioMedicine. 2018;37:410–6.PubMedPubMedCentralCrossRef
39.
Kohl TA, Harmsen D, Rothgänger J, Walker T, Diel R, Niemann S. Harmonized genome wide typing of tubercle bacilli using a web-based gene-by-gene nomenclature system. EBioMedicine. 2018;34:131–8.PubMedPubMedCentralCrossRef
40.
Liu CH, Li HM, Lu N, Wang Q, Hu YL, Yang X, et al. Genomic sequence based scanning for drug resistance-associated mutations and evolutionary analysis of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis. J Infect. 2012;65:412–22.PubMedCrossRef
41.
Ahmad S, Mokaddas E. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Respir Med. 2009;103:1777–90.PubMedCrossRef
42.
Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011;55:2032–41.PubMedPubMedCentralCrossRef
43.
Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, et al. Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol. 2014;52:781–9.PubMedPubMedCentralCrossRef
44.
Vilchèze C, Jacobs WR. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectrum. 2014. p. 2.
45.
Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006;312:1944–6.PubMedCrossRef
46.
Ahmad S, Mokaddas E. Recent advances in proper management of multidrug-resistant tuberculosis. Kuw Med J. 2018;50:146–60.
47.
Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol. 2010;48:300–1.PubMedCrossRef
48.
Hoffner S, Angeby K, Sturegård E, Jönsson B, Johansson A, Sellin M, et al. Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience. Int J Tuberc Lung Dis. 2013;17(11):1486–90.PubMedCrossRef
49.
Piersimoni C, Mustazzolu A, Giannoni F, Bornigia S, Gherardi G, Fattorini L. Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum. J Clin Microbiol. 2013;51:291–4.PubMedPubMedCentralCrossRef
50.
Pang Y, Zhu D, Zheng H, Shen J, Hu Y, Liu J, et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis. 2017;17:711.PubMedPubMedCentralCrossRef
51.
Zhang Y, Chiu Chang K, Leung CC, Wai Yew W, Gicquel B, Fallows D, et al. ‘Zs-MDR-TB’ versus ‘Zr-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility. Emerg Microbes Infect. 2012;1:e5.PubMedPubMedCentralCrossRef
52.
Hanekom M, van Pittius NC, McEvoy C, Victor TC, Van Helden PD, Warren RM. Mycobacterium tuberculosis Beijing genotype: a template for success. Tuberculosis (Edinb). 2011;91:510–23.CrossRef
53.
Hoffner S, Sahebi L, Ansarin K, Sabour S, Mohajeri P. Mycobacterium tuberculosis of the Beijing genotype in Iran and the World Health Organization Eastern Mediterranean Region: a meta-analysis. Microb Drug Resist. 2018;24:693–8.PubMedCrossRef
54.
Varghese B, Supply P, Allix-Béguec C, Shoukri M, Al-Omari R, Herbawi M, et al. Admixed phylogenetic distribution of drug resistant Mycobacterium tuberculosis in Saudi Arabia. PLoS ONE. 2013;8:e55598.PubMedPubMedCentralCrossRef
55.
Poudel A, Maharjan B, Nakajima C, Fukushima Y, Pandey BD, Beneke A, et al. Characterization of extensively drug-resistant Mycobacterium tuberculosis in Nepal. Tuberculosis (Edinburgh). 2013;93:84–8.CrossRef
56.
Chen H, He L, Huang H, Shi C, Ni X, Dai G, et al. Mycobacterium tuberculosis lineage distribution in Xinjiang and Gansu Provinces. China. Sci Rep. 2017;7:1068.PubMedCrossRef
57.
Nikolayevskyy V, Niemann S, Anthony R, van Soolingen D, Tagliani E, Ködmön C, et al. Role and value of whole genome sequencing in studying tuberculosis transmission. Clin Microbiol Infect. 2019;25(11):1377–82.PubMedCrossRef
58.
Appelgren A, Morquin D, Dufour S, Le Moing V, Reynes J, Lotthé A, et al. Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016. J Hosp Infect. 2017;97:414–7.PubMedCrossRef
59.
Walker TM, Lalor MK, Broda A, Ortega LS, Morgan M, Parker L, et al. Assessment of Mycobacterium tuberculosis transmission in Oxfordshire, UK, 2007–12, with whole pathogen genome sequences: an observational study. Lancet Respir Med. 2014;2:285–92.PubMedPubMedCentralCrossRef
60.
61.
Al-Ghafli H, Kohl TA, Merker M, Varghese B, Halees A, Niemann S, et al. Drug-resistance profiling and transmission dynamics of multidrug-resistant Mycobacterium tuberculosis in Saudi Arabia revealed by whole genome sequencing. Infect Drug Resist. 2018;11:2219–29.PubMedPubMedCentralCrossRef
62.
Lalor MK, Casali N, Walker TM, Anderson LF, Davidson JA, Ratna N, et al. The use of whole-genome sequencing in cluster investigation of a multidrug-resistant tuberculosis outbreak. Eur Respir J. 2018;51:1702313.PubMedCrossRef
Metadata
Title
Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB
Authors
Noura M. Al-Mutairi
Suhail Ahmad
Eiman M. Mokaddas
Publication date
01-12-2019
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2019
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-019-0397-2

Other articles of this Issue 1/2019

European Journal of Medical Research 1/2019 Go to the issue

Research

Early prolonged ambulatory cardiac monitoring in stroke (EPACS): an open-label randomised controlled trial

Research

The impact of medical documentation assistants on process performance measures in a surgical emergency department

Research

Clinical characteristics of epithelioid hemangioendothelioma: a single-center retrospective study

Research

Nickel–titanium arched shape-memory alloy connector combined with bone grafting in the treatment of scaphoid nonunion

Research

The value of tranexamic acid for patients with preoperative anemia in primary total knee arthroplasty

Research

Correlation analysis of serum thyroid stimulating hormone with acute cerebrovascular disease